Invion

Subscribe to receive announcements and updates from Invion.

New investors

Home

Announcements

Updates

Lato

MELBOURNE (AUSTRALIA) 07 July 2023:  Invion Limited (ASX: IVX) (“Invion” or the “Company”) understands that preliminary findings from the Phase II Prostate Cancer Trial undertaken by RMW Cho Group Limited (RMW) and its related companies will be presented at the Australian and New Zealand Urogenital and Prostate (ANZUP) Annual Scientific Meeting 2023. RMW is the patent holder and licensor of the Photosoft technology.

RMW is presenting a poster at the meeting in Melbourne on Monday the 10th of July on the status of the trial. Details are not available to Invion at this time since it is not involved with this trial. The Company will provide further information to the ASX in compliance with its continuous disclosure obligations.

RMW to Present at ANZUP Cancer Trials Group Annual Scientific Meeting 2023